BBLG on Nasdaq
Bone Biologics Corp
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Invacare, Avanos Medical or MSA Safety, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2020
Where the money goes
Where each dollar of revenue went, fiscal 2020
- Research and development0¢$340.7K
- Other costs100¢$1.1B
- Income tax0¢$1.6K
Out of $1.1B in revenue.43 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $1.1M | $2.1M |
| General and administrative | $2.2M | $2.1M |
| Total operating expenses | $3.2M | $4.2M |
| Loss from operations | -$3.2M | -$4.2M |
| Change in fair value of warrant liability | $4.0K | $51.1K |
| Interest income | $122.0K | $55.7K |
| Total other income | $126.0K | $106.7K |
| Net loss | -$3.1M | -$4.1M |
| Deemed dividend on warrant inducements | -$3.2M | |
| Net loss attributable to common stockholders | -$3.1M | -$7.3M |
| Weighted average shares outstanding - basic | 1.2M shares | 253.0K shares |
| Weighted average shares outstanding - diluted | 1.2M shares | 253.0K shares |
| Loss per share - basic | -$2.65 | -$28.96 |
| Loss per share - diluted | -$2.65 | -$28.96 |
Every line of the balance sheet in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $5.3M | $3.3M | |
| Advances on research and development contract services | $209.0K | $258.1K | |
| Prepaid insurance | $232.9K | $268.2K | |
| Interest Receivable | $9.9K | ||
| Prepaid expenses | $10.0K | $10.0K | |
| Total current assets | $5.8M | $3.9M | |
| Total assets | $5.8M | $3.9M | |
| Accounts payable and accrued expenses | $417.9K | $373.0K | |
| Warrant liability | $703 | $4.7K | |
| Total current liabilities | $418.6K | $377.7K | |
| Total liabilities | $418.6K | $377.7K | |
| Common stock, $0.001 par value per share; 100,000,000 shares authorized; 1,795,260 and 492,417 shares issued and outstanding at December 31, 2025 and 2024, respectively | $1.8K | $492 | |
| Additional paid-in capital | $93.5M | $88.5M | |
| Accumulated deficit | -$88.1M | -$85.0M | |
| Total stockholders equity | $5.4M | $3.5M | $2.9M |
| Total liabilities and stockholders equity | $5.8M | $3.9M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 20.0M shares | 20.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 100.0M shares | 100.0M shares | |
| Common stock, shares issued | 1.8M shares | 492.4K shares | |
| Common stock, shares outstanding | 1.8M shares | 492.4K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$3.1M | -$4.1M |
| Stock-based compensation | $256.4K | $188.8K |
| Change in fair value of warrant liability | -$4.0K | -$51.1K |
| Advances on research and development contract services | $49.1K | $70.8K |
| Prepaid insurance | $35.2K | $104.2K |
| Interest receivable | -$9.9K | |
| Accounts payable and accrued expenses | $91.0K | $89.8K |
| Accrued legal settlement | -$415.0K | |
| Net cash used in operating activities | -$2.7M | -$4.1M |
| Proceeds from issuance of common shares from ATM, net of costs | $347.5K | $1.1M |
| Proceeds from sale of common stock, warrants, and pre-funded warrants in public offering, net of offering costs | $4.4M | $1.5M |
| Proceeds from issuance of common shares from warrant inducement, net of costs | $1.8M | |
| Exercise of pre-funded warrants | $662 | |
| Net cash provided by financing activities | $4.7M | $4.4M |
| Net increase in cash | $2.0M | $298.6K |
| Options issued to settle accrued bonus | $46.2K | $77.4K |
| Deemed dividend warrant inducement | $3.2M |
Former names
Recent filings
- Oct 13, 202625-NSE
- Sep 30, 20264
- Sep 30, 20264
- Sep 30, 20264
- Sep 30, 20264
- Sep 29, 20268-K
- Sep 16, 20268-K
- Aug 28, 2026DEF 14A
- Aug 18, 2026PRE 14A
- Aug 14, 202610-Q
- Jul 24, 2026424B3
- Jul 24, 2026EFFECT
- Jul 23, 20268-K
- Jul 20, 2026DEFA14A
- Jul 17, 2026S-3
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9